Hypotheses
499 hypotheses · 178 with trials running
Showing 25 items
Lasting remission
relapsing MSConfirmedPhase 426 trials · 2 running · Alemtuzumab, Cladribine
Stop relapses
relapsing MSConfirmedPhase 421 trials · 1 running · Alemtuzumab, Cladribine
Slow progression
relapsing MSConfirmedPhase 415 trials · 2 running · Alemtuzumab, Cladribine
Prevent or delay MS
early MS (CIS or RIS)Supported by one trialPhase 31 trial · 0 running · Cladribine
Lasting remission
early MS (CIS or RIS)Supported by one trialPhase 31 trial · 0 running · Cladribine
Slow progression
early MS (CIS or RIS)Supported by one trialPhase 31 trial · 0 running · Cladribine
Stop relapses
early MS (CIS or RIS)Supported by one trialPhase 31 trial · 0 running · Cladribine
Lasting remission
MS (type not specified)Results pendingPhase 43 trials · 0 running · Cladribine
Slow progression
MS (type not specified)Results pendingPhase 22 trials · 0 running ·
Lasting remission
relapsing and progressive MSBeing testedPhase 47 trials · 3 running · Alemtuzumab, Cladribine
Protect nerves
relapsing and progressive MSBeing testedPhase 43 trials · 2 running · Cladribine
Lasting remission
secondary progressive MSBeing testedPhase 42 trials · 1 running · Cladribine
Slow progression
secondary progressive MSBeing testedPhase 42 trials · 1 running · Cladribine
Stop relapses
relapsing and progressive MSBeing testedPhase 32 trials · 1 running ·
Protect nerves
relapsing MSBeing testedPhase 41 trial · 1 running · Alemtuzumab
Lasting remission
primary progressive MSBeing testedPhase 2/31 trial · 1 running · Cladribine
Slow progression
primary progressive MSBeing testedPhase 2/31 trial · 1 running · Cladribine
Repair myelin
relapsing MSNo clear answerPhase 42 trials · 0 running · Alemtuzumab, Cladribine
Lasting remission
NMOSDNo clear answerPhase 2/32 trials · 0 running ·
Slow progression
relapsing and progressive MSNo clear answerPhase 12 trials · 0 running · Alemtuzumab
Protect nerves
secondary progressive MSNo clear answerPhase 41 trial · 0 running · Cladribine
Repair myelin
MS (type not specified)No clear answerPhase 41 trial · 0 running · Cladribine
Slow progression
NMOSDNo clear answerPhase 2/31 trial · 0 running ·
Stop relapses
NMOSDNo clear answerPhase 1/21 trial · 0 running ·
Stop relapses
secondary progressive MSNo clear answerPhase 41 trial · 0 running · Cladribine
How a status is decided
A hypothesis is Confirmed when two or more controlled phase 3 trials met their main goal, or when one did and a medicine of the same approach is approved in the EU or the US for that use. With one positive phase 3 trial and no approval it is Supported by one trial. Analyses that only compare an active comparator with placebo, such as interferon beta against placebo inside a laquinimod trial, do not count as the tested medicine’s result.
- Confirmed
- Two or more controlled phase 3 trials met their main goal, or one did and a medicine of this approach is approved for this use.
- Supported by one trial
- One controlled phase 3 trial met its main goal. It needs a second trial or regulatory approval to count as confirmed.
- Promising
- Worked in a controlled phase 2 trial. A signal, not proof.
- Mixed
- Controlled trials disagree.
- Results pending
- Trials finished, but not all results are read yet.
- Being tested
- Trials are running now. No verdict yet.
- Failed in phase 2
- Controlled phase 2 trials did not meet their main goal for this group.
- Failed in phase 3
- Controlled phase 3 trials did not meet their main goal for this group. This does not rule out the mechanism in other groups or with other medicines.
- No clear answer
- Tried, but no controlled phase 2 or 3 result yet.
- Not yet tested
- Proposed or suggested by genetics. Not yet tested in MS.
Unread results can leave a status pending. Two or more phase 3 trials that met their goal, with none against, give a verdict even when an extension study at the same phase has no readable result.
“Failed in phase 3” applies to the patient group shown. A hypothesis can fail in primary progressive MS and work in relapsing MS.
Not yet tested items come from two places: proposed hypotheses, and genes linked to MS by human genetics that existing medicines act on but that have never been tried in MS.
Nothing here is linked or edited by hand. To report an error, use the contact form; we fix the rule, so the fix applies everywhere.